Evidence map›Paper›PMID 33828191›Full record

ArticleScientific reports2021

Enhancement of tumor tropism of mPEGylated nanoparticles by anti-mPEG bispecific antibody for ovarian cancer therapy.

Wen-Wei Lin, Yi-An Cheng, Chia-Ching Li, Kai-Wen Ho, Huei-Jen Chen, I-J U Chen, Bo-Cheng Huang, Hui-Ju Liu, Yun-Chi Lu, Chiu-Min Cheng and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.6field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 1 country.

Wen-Wei Lin *Department of Laboratory Medicine, School of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan.
Yi-An Cheng *Drug Development and Value Creation Research Center, Kaohsiung Medical University, Kaohsiung, Taiwan.
Chia-Ching LiDrug Development and Value Creation Research Center, Kaohsiung Medical University, Kaohsiung, Taiwan.
Kai-Wen HoGraduate Institute of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan.
Huei-Jen ChenGraduate Institute of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan.
I-J U ChenDrug Development and Value Creation Research Center, Kaohsiung Medical University, Kaohsiung, Taiwan.
Bo-Cheng HuangInstitute of Biomedical Sciences, National Sun Yat-Sen University, Kaohsiung, Taiwan.
Hui-Ju LiuGraduate Institute of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan.
Yun-Chi LuDrug Development and Value Creation Research Center, Kaohsiung Medical University, Kaohsiung, Taiwan.
Chiu-Min ChengDepartment of Aquaculture, National Kaohsiung University of Science and Technology, Kaohsiung, Taiwan.
Ming-Yii HuangDepartment of Radiation Oncology, Cancer Center, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan.
Hung-Wen LaiEndoscopic and Oncoplastic Breast Surgery Center, Comprehensive Breast Cancer Center, Changhua Christian Hospital, 135 Nanxiao Street, Changhua, 500, Taiwan. 143809@cch.org.tw.
Tian-Lu ChengGraduate Institute of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan. tlcheng@kmu.edu.tw.
Kaohsiung Medical University · TWChanghua Christian Hospital · TWKaohsiung Medical University Chung-Ho Memorial Hospital · TWNational Kaohsiung Marine University · TWNational Sun Yat-sen University · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ovarian cancer is highly metastatic, with a high frequency of relapse, and is the most fatal gynecologic malignancy in women worldwide. It is important to elevate the drug susceptibility and cytotoxicity of ovarian cancer cells, thereby eliminating resident cancer cells for more effective therapeutic efficacy. Here, we developed a bispecific antibody (BsAb; mPEG × HER2) that can easily provide HER2

Indexed as

AnimalsAntibodies, BispecificCell Line, TumorDoxorubicinDrug CarriersDrug Delivery SystemsFemaleHumansMCF-7 CellsMiceMice, Inbred BALB CNanoparticlesNeoplasm Recurrence, LocalOvarian NeoplasmsPolyethylene GlycolsTropismAntibodies, BispecificDoxorubicinDrug Carriersliposomal doxorubicinmonomethoxypolyethylene glycolPolyethylene Glycols

Identifiers

PMID33828191
PMCPMC8027450
OpenAlexW3150094683

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.